Worldwide Market for Clinical Laboratory Services, 11th Edition - Science and Medicine Group

The definitive global assessment of the clinical laboratory services industry — sized, segmented, and forecast through 2030.

Now in its 11th edition, Kalorama Information's flagship review of clinical laboratory services gives decision-makers a rigorous, independent read on where diagnostic testing revenue sits today and where it is heading. Built on a 2025 base year, with historical data spanning 2020–2024 and forecasts running through 2030, the report is the reference stakeholders use to size markets, benchmark competitors, and pressure-test strategy against demographic, clinical, technological, and reimbursement realities.

Why this report matters now

Clinical laboratories sit at the center of the diagnostic process and are among the largest end-users of in vitro diagnostics, informing decisions across chemistry, hematology, immunology, microbiology, anatomic pathology, genetics, and molecular diagnostics. The care setting for those tests is shifting quickly — outward to outpatient, ambulatory, retail, and home-based collection, and simultaneously inward, as high-complexity molecular and genomic work concentrates in reference labs, academic centers, and specialty facilities. Layer on aging populations, rising chronic disease burden, oncology's growing dependence on molecular and companion diagnostics, persistent pricing and reimbursement pressure, staffing shortages, and accelerating consolidation, and the competitive terrain is being redrawn. This edition maps that terrain with data, not conjecture.

What's inside

Market sizing and forecasts. Global revenues at the service-provider level, with year-by-year historical performance, 2025–2030 projections, and CAGRs supplied for every major segment.

Testing services by specialty. Discrete sizing, trend lines, and growth forecasts for six segments: essential and routine testing (clinical chemistry, hematology, coagulation, endocrinology), immunology and microbiology, cytology and histology, genetic testing, toxicology (drugs of abuse), and COVID-19 — including where post-pandemic normalization is redistributing volume toward traditional and specialized testing.

Market by provider group. Analysis breakdowns across hospital and acute-care labs, physician and outpatient providers, and independent and reference laboratories, contextualized with hospital-bed and physician-density benchmarks and settings such as nursing, home health, dialysis, and pharmacy-based labs.

Regional depth across four regions and 15 countries. North America (United States, Canada); EMEA (Germany, France, Italy, Spain, United Kingdom, Switzerland); Asia Pacific (Japan, China, India, South Korea, Australia); and Latin America (Brazil, Mexico) — each with country-level market values, performance histories, and growth projections, plus industry-structure detail for key markets.

Regulatory and reimbursement intelligence. Practical coverage of the forces that move margins: CLIA structure and certification trends, laboratory-developed test regulation, EU IVDR, Medicare reimbursement trajectories, PAMA and the CARES Act, SALSA, ADLT designations, ESRD consolidated billing, commercial-payer dynamics, and pricing transparency.

Competitive analysis and company profiles. A market-share analysis of leading providers plus profiles of the companies shaping global competition — among them ARUP, BioReference Health, DaVita, Eurofins Scientific, Exact Sciences, Guardant Health, H.U. Group, Labcorp, Medicover, Myriad Genetics, Natera, Quest Diagnostics, Siemens Healthineers, Sonic Healthcare, SYNLAB, and Unilabs — with corporate detail, revenue histories, and acquisition, alliance, and partnership activity.

The trends that will define 2025–2030. A dedicated analysis of AI, machine learning, and lab automation; molecular and advanced testing; digital pathology; multiplex testing; personalized medicine; consolidation and centralized networks; pricing and reimbursement pressure; and staffing shortages.

Methodology you can stand behind

Findings draw on primary interviews with industry officials, consultants, providers, and government sources, complemented by secondary research across company filings, databases, investment reports, and medical and business literature. Revenues are recognized at the service-provider level across payer types, with contractual adjustments and fee arrangements accounted for.

Market research for key stakeholders and decision-makers

Worldwide Market for Clinical Laboratory Services, 11th Edition is designed for C-suite executives and strategy teams at diagnostics and laboratory companies, IVD manufacturers benchmarking end-market demand, competitors evaluating market share and white-space opportunities, investors and corporate development teams assessing consolidation prospects, and marketing and commercial leaders seeking a defensible view of segment and regional growth.

Please Note: Single user allows for up to 3 users for this report.
Show more